Get the Stockscreener App
28.57
0.44%
0.14
Lenz Therapeutics Inc stock is traded at $28.57, with a volume of 82,961.
It is up +0.44% in the last 24 hours and up +10.76% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$28.43
Open:
$29.23
24h Volume:
82,961
Relative Volume:
0.54
Market Cap:
$781.18M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-73.92M
1W Performance:
+1.22%
1M Performance:
+10.76%
6M Performance:
+73.48%
1Y Performance:
+0.00%
1-Day Range:
$28.11
$29.50
1-Week Range:
$26.12
$29.50
52-Week Range:
$14.42
$31.00
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
445 MARINE VIEW AVE SUITE 320, DEL MAR
Lenz Therapeutics Inc Stock (LENZ) Latest News
LENZ Therapeutics (LENZ) to Release Earnings on Wednesday - MarketBeat
Registration Open for CME/CE-Accredited Free Event Nov 7 - InvisionMag
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 - The Manila Times
LENZ Therapeutics Insider Buyers See Boost After Market Cap Rose US$97m - Simply Wall St
Corxel and LENZ share positive results from Phase III China trial - The Pharma Letter
LENZ reports positive Chinese study data for far-sightedness drug - MSN
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships - AOL
Wescott Financial Advisory Group LLC Acquires 2,154 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints - MarketWatch
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 - ForexTV.com
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial - The Bakersfield Californian
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average Price Target from Analysts - MarketBeat
Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 - Yahoo Finance
Mcf Energy Ltd (MCF-X) QuotePress Release - The Globe and Mail
LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment - Marketscreener.com
Why LENZ Therapeutics Stock Hit A New 52-Week High Today - Benzinga
One new option listing and ten option delistings on October 21st - TipRanks
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - The Manila Times
LENZ Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - Marketscreener.com
Behind the Bell: LENZ Therapeutics - Nasdaq
FY2028 Earnings Estimate for LENZ Issued By Leerink Partnrs - MarketBeat
Presbyopia Market on Track for Major Expansion by 2034, - openPR
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail
Preterm Birth and PROM Testing Market Expected to Grow at 8.6% CAGR, projected to Reach USD 562.1 million by 2034 | States Transparency Market Research, Inc. - Yahoo Finance
Lenz Co. stock soars to 52-week high, hits $26.18 By Investing.com - Investing.com Canada
Lucy Therapeutics Appoints Kim Drapkin as Board Chair - BioSpace
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - Yahoo Finance
TJX Companies (TJX-N) QuotePress Release - The Globe and Mail
Dimensional Fund Advisors LP Increases Holdings in Koss Co. (NASDAQ:KOSS) - Defense World
Creative Planning Buys 296 Shares of PVH Corp. (NYSE:PVH) - Defense World
ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Large Increase in Short Interest - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by The Manufacturers Life Insurance Company - MarketBeat
Neumora Therapeutics executive sells over $200k in company stock By Investing.com - Investing.com Australia
Neumora Therapeutics executive sells over $200k in company stock - Investing.com India
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Robert A. Lenz Sells 5,563 Shares - MarketBeat
Neumora Therapeutics Inc. [NMRA] Records 50-Day SMA of $12.22 - Knox Daily
Marshall Wace LLP Invests $390,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Market Momentum Report: Neumora Therapeutics Inc. (NMRA)’s Positive Close at 14.74 - The Dwinnex
LENZEyeing A Slice Of The Presbyopia Pie - RTTNews
LENZ stock touches 52-week high at $25.85 amid market optimism - Investing.com Canada
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases - ForexTV.com
Potential Price Increase for Neumora Therapeutics Inc. (NMRA) After Recent Insider Activity - Knox Daily
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Canada Pension Plan Investment Board Makes New $26,000 Investment in Mesa Laboratories, Inc. (NASDAQ:MLAB) - Defense World
Xponance Inc. Cuts Position in Darling Ingredients Inc. (NYSE:DAR) - Defense World
EURETINA 2024: CRISPR-Cas mediated base editing approaches for CRB1 related retinal dystrophy - Modern Retina
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences - The Manila Times
Metavesco Acquires Assets From Epic Labor - The Manila Times
Achieve, INmune, Lenz gain on bullish initiations from Raymond James - MSN
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lenz Therapeutics Inc Stock (LENZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chevallard Daniel R. | Chief Financial Officer |
May 14 '24 |
Buy |
15.68 |
3,188 |
49,988 |
3,188 |
| MCCOLLUM JAMES W | Director |
May 13 '24 |
Buy |
15.99 |
31,332 |
501,093 |
525,565 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 21 '24 |
Buy |
15.03 |
998,009 |
15,000,075 |
3,319,339 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):